A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Trial details
- Registry ID
- NCT03899636
- Drugs studied
- Modified FOLFIRINOX Regimen, NanoKnife System
TrialRedline tracks 1 clinical trial sponsored by Angiodynamics, Inc.: 1 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic CancerNCT03899636 | Modified FOLFIRINOX Regimen, NanoKnife System | Active not recruiting | 2025-04Estimated |
Names as written in the registry records.